Personalized cancer drugs, designed computationally.
Cancer is the forcing function — 20M new cases a year, with 35M+ projected by 2050. The next platform layer of medicine is not another drug catalogue; it is therapeutic computation.
BEIT builds the computational chemistry engine underneath the AI drug-discovery era — quantum-ready, not quantum-dependent, and ready for the move from pharma pilots to hospital-grade infrastructure.
Cancer sets the deadline.
By 2050, 35M+ new cases annually. Source: WHO/IARC, 2024.
Two stories changed the floor.
Personalized therapeutic reasoning has already moved from theory into visible frontier practice.
Founder-mode oncology: diagnostics, tumour data, AI reasoning, expert networks and therapeutic access orchestrated around one patient.
Sequencing, ChatGPT, protein modelling, custom analysis and academic RNA collaboration compressed into one bespoke intervention.
Not statistical proof — proof that the ingredients of a new system have arrived.
Founder-mode medicine cannot stay rare.
The frontier exists today, but it is accessible only to exceptional people with exceptional networks.
Elite patients orchestrate diagnostics, data, AI and experts to assemble bespoke care.
Most patients cannot become the CEO of their own cancer program.
The workflow must become safe, AI-driven infrastructure that lives inside the hospital.
Personalized therapeutic reasoning should be available for everyone.
BEIT starts where the bottleneck begins.
The earliest computational phase, where better decisions remove weak molecules before expensive failure.
Candidate poses against target pockets.
Separate plausible binders from false positives.
Model movement, stability and binding behaviour.
Estimate free-energy changes for lead choices.
Address difficult chemistry beyond approximations.
Improve real discovery decisions now. Build the basis for patient-specific design later.
From search for drugs to design of drugs.
Screen vast chemical spaces for molecules that might happen to fit a target.
Compute, generate, rank and refine molecules for a specific biological state — compute → generate → refine, on repeat.
The long-term unit of work: one molecule, one tumour, one patient, one inference run.
AI needs molecular truth.
Generic AI can generate hypotheses. It cannot replace physics, chemistry and validation.
Candidate generation across large chemical spaces — hypotheses at a scale humans cannot enumerate.
Binding-affinity truth where fast models fail. Physics earns its place where decisions are expensive.
Industrial throughput for discovery workflows today — pharma-grade rigour, not demoware.
Classical value now; future acceleration later. Quantum-ready, not quantum-dependent.
The computational chemistry engine underneath the AI drug-discovery era — quantum-ready, not quantum-dependent.
Pharma first. Patients ultimately.
Built together with the right pharma partners — shared workflows, validation standards and trust — shifting the market.
Focused pilots validate the stack and reveal discovery economics where decisions already happen.
Move from projects to reusable workflows for discovery teams, computational centres and hospital pilots.
The ultimate customer is the patient, accessed through hospitals, oncologists and tumour boards.
SpaceX takes us toward Mars. BEIT takes us toward personalized cancer drugs.
Compress the cost and time of personalized drug discovery, and turn founder-mode medicine into scalable hospital infrastructure.